Media Room

For media inquiries, please contact:

Dawn Kalmar
Chief Communications Officer

Tel: 781-303-8302
dkalmar@stoketherapeutics.com

Media Downloads

Fact Sheet

TANGO Explainer

Fact Sheet

Dravet Syndrome

Photo

Ian F. Smith, Interim Chief Executive Officer

Photo

Isabel Aznarez, Ph.D., Senior Vice President, Head of Research and Co-Founder

Photo

Edward M. Kaye, M.D., Advisor and Board Member

Illustration

TANGO-ASO

Logo

Stoke Therapeutics

Stoke In the News

Experts from Stoke are consulted for input to inform news coverage about our innovative science, the serious diseases we are working to address, and the industry we are proud to be a part of.

Learn More

Latest Press Releases

Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome

September 2, 2025

Read more

Stoke Therapeutics to Present at Upcoming Investor Conferences in September 2025

August 28, 2025

Read more

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress

August 25, 2025

Read more

Learn more about our science

View all our publications and presentations

Featured Publications

Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet syndrome

Science Translational Medicine

August 26, 2020

Read Full Article

Antisense oligonucleotide modulation of non-productive alternative splicing upregulates gene expression

Nature Communications

July 9, 2020

Read Full Article

More About Stoke on Twitter